HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cygnus Inc.

Division of Johnson & Johnson
www.cygn.com

Latest From Cygnus Inc.

Cracking Open the IPO Window for Pre-Commercial Device Companies

DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.
Medical Device Business Strategies

Cracking Open the IPO Window for Pre-Commercial Device Companies

DexCom's is a bellwether IPO: if it holds its value, it could open the door for other pre-commercial device businesses. If it doesn't, it could keep it shut-as it's been since the class of 1995-96 device companies disappointed investors by missing their commercial targets.
Medical Device Business Strategies

Diabetes Monitoring Start-Ups:Building a Better Mousetrap or a Whole New Paradigm?

All facets of diabetes are a big focus of start-up and venture capital interest these days--insulin, blood-glucose testing, and new small-molecule drugs. Blood glucose monitoring is one of the few areas of in vitro diagnostics that attracts a significant amount of investor interest. Startups in this field pick one of two tacts: to try to change the testing paradigm with revolutionary technologies or to introduce incremental improvements, which could help attract big corporate partners.
Medical Device Business Strategies

Top Ten Pitfalls to New Medical Device Launches

It is not uncommon for a new medical device to fail to initially live up to projected sales expectations. Early disappointing product sales can produce a hole that a company can spend a long time trying to dig its way out of, having to battle a declining stock price, decreased investor confidence, lower company valuations, and diminished access to capital. The end result may be that both the product and the company are never able to fully recover from the early set-back. Many initial disappointing product roll-outs can be attributed to problems that commonly confront device companies. Product companies have adopted successful strategies to anticipate and overcome many of these issues, and thereby increase the chances of a new product coming strong out-of-the blocks.
Medical Device Reimbursement
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Biosensors
  • Medical Devices
    • Monitoring Equipment & Devices
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Johnson & Johnson
  • Senior Management
  • John C Hodgman, Chmn., Pres. & CEO
    Craig W Carlson, SVP, CFO & COO
    Neil R Ackerman, PhD, SVP, R&D, Scientific Affairs & CTO
  • Contact Info
  • Cygnus Inc.
    Phone: (650) 369-4300
    400 Penobscot Dr.
    Redwood City, CA 94063
    USA
UsernamePublicRestriction

Register